ストックスクリーナーアプリを入手
2.44
3.17%
-0.08
アフターアワーズ：
2.63
0.19
+7.79%
前日終値:
$2.52
開ける：
$2.52
24時間の取引高:
272.60K
Relative Volume:
1.25
時価総額：
$110.40M
収益：
$8,000
当期純損益:
$-33.58M
株価収益率:
-2.8581
EPS:
-0.8537
ネットキャッシュフロー:
$-27.88M
1週間 パフォーマンス:
-8.27%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
-8.96%
1年 パフォーマンス:
-29.89%
1日の値動き範囲:
$2.425
$2.535
1週間の範囲:
$2.425
$2.77
52週間の値動き範囲:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
名前
Genelux Corp
セクター
電話
805-267-9889
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.44 | 123.97M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Lake Street | Buy |
| 2024-10-29 | 開始されました | Guggenheim | Buy |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-11-27 | 開始されました | H.C. Wainwright | Buy |
| 2023-09-12 | 開始されました | Maxim Group | Buy |
| 2023-02-15 | 開始されました | The Benchmark Company | Speculative Buy |
すべてを表示
Genelux Corp (GNLX) 最新ニュース
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Equities Analysts Offer Predictions for Genelux Q3 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst - TipRanks
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer - Quiver Quantitative
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - Yahoo Finance
Genelux (NASDAQ:GNLX) Issues Earnings Results - MarketBeat
Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway - Stock Titan
GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary - TradingView
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51 - Sahm
Genelux Corp expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Genelux Corp (GNLX) Balance Sheet - TradingKey
Genelux Corp (GNLX) Cash Flow - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Income Statement - TradingKey
GNLX|Genelux Corp|Price:2.890|Chg%:-0.070 - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux (NASDAQ:GNLX) Shares Down 2.4%Should You Sell? - marketbeat.com
Insider Shake-Up at Genelux Corp Sparks Investor Attention - TipRanks
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com - Investing.com Nigeria
Form 8K Genelux Corp For: 22 June By Investing.com - Investing.com South Africa
Genelux (GNLX) 2026 meeting backs director John Smither and auditor - Stock Titan
Genelux (GNLX) director receives RSU and stock option grants - Stock Titan
Genelux (GNLX) director receives RSUs and stock options in new grant - Stock Titan
GENELUX (GNLX) CFO receives 278,906 restricted stock units as equity grant - Stock Titan
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen - Stock Titan
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan - Stock Titan
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants - Stock Titan
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan - Stock Titan
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant - Stock Titan
GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards - Stock Titan
Genelux Corp (GNLX) Institutional Confidence - TradingKey
Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GNLX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D FocusRevenue Warning Signal - po-news-eg.net
Genelux Corporation (GNLX) Shows Uptick: Testing Key Resistance at $3.13Float Adjusted Cap - dars.gov.et
Genelux Corp (GNLX) 財務データ
収益
当期純利益
現金流量
EPS
Genelux Corp (GNLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cappello Joseph | Chief Technical Officer |
Aug 04 '26 |
Sale |
2.95 |
653 |
1,924 |
328,737 |
| Zindrick Thomas | President and CEO |
Aug 04 '26 |
Sale |
2.95 |
3,023 |
8,905 |
1,260,890 |
| Smither John W | Director |
Jul 01 '26 |
Sale |
2.91 |
12,000 |
34,898 |
91,403 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):